PTC299

Overview

PTC299 is an orally active inhibitor of VEGFA mRNA translation that selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of dihydroorotate dehydrogenase (DHODH) . PTC299 shows good oral bioavailability and lack of off-target kinase inhibition and myelosuppression. PTC299 can be useful for the research of hematologic malignancies.

Application

Products | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > VEGFR | Products > Signaling Pathways > Dihydroorotate Dehydrogenase | Products > Signaling Pathways > DNA/RNA Synthesis

Product Information

• Catalog No.: HY-124593
• CAS No.: 1256565-36-2
• Molecular Formula: C25H20Cl2N2O3
• Molecular Weight: 467.34
• Purity: 99.71%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 0.83 mg/mL (1.78 mM); Clear solution
• Availability: In-stock

Source

Original product source